LB 933 protects Nebraska healthcare practitioners who recommend medical cannabis under the Nebraska Medical Cannabis Patient Protection Act. The bill shields doctors, nurses, and other licensed providers from disciplinary action - including license penalties or civil fines - when they provide a written recommendation or state in their professional opinion that a patient may benefit from cannabis for medical treatment. This applies specifically to recommendations for conditions like chronic pain or nausea, not general cannabis use. The law directly affects healthcare professionals who interact with medical cannabis patients in Nebraska.
LB 955 allows pharmacists in Nebraska to form written practice agreements with physician assistants (PAs) who work under collaborative agreements with physicians. These agreements enable PAs to coordinate with pharmacists to provide pharmaceutical care under specific written protocols for monitored or initiated therapies. The bill requires pharmacists to notify both the Pharmacy Board and the PA's licensing board about agreements, include signed protocols, and review agreements every two years. This change directly affects pharmacists, PAs, and their supervising physicians by creating a formalized process for collaborative patient care.
Nebraska Legislative Bill LB 722 amends the Behavioral Health Services Fund to explicitly include services for individuals with substance use disorder. The bill clarifies that funds can now be used for behavioral health services specifically for people with substance use disorder, aligning with existing provisions for serious mental illness. This change, which references the definition in Section 71-430, ensures the fund’s resources directly support treatment and housing-related assistance for this population without creating new funding. The bill affects Nebraskans seeking behavioral health services, particularly those with substance use disorder who qualify under the fund’s existing eligibility criteria.
Nebraska LB 677 updates the state's medical cannabis framework by clarifying key definitions (like "cannabis products" and "caregivers"), establishing new licensing rules for cultivators and dispensaries, and imposing a special sales tax on medical cannabis sales. It prohibits open cannabis containers in vehicles, removes medical cannabis from existing marijuana tax categories, and directs tax revenue to specific state funds. The bill directly affects qualified patients, registered caregivers, cannabis businesses, and the Nebraska Liquor Control Commission, which now oversees regulation. It also repeals outdated provisions and harmonizes existing laws, though it remains pending in committee as of March 2025.
This bill eliminates numerous state advisory groups, boards, and commissions - including the Climate Assessment Response Committee, Women's Health Initiative Advisory Council, and Palliative Care Act - and removes their funding. It also modifies department responsibilities, such as adjusting the Board of Mental Health Practice and the Department of Health and Human Services. The bill specifically terminates the Whiteclay Public Health Emergency Task Force and streamlines overlapping government structures by repealing obsolete provisions. These changes aim to simplify state agency operations by removing redundant entities and consolidating functions.
LB 326 amends Nebraska's insurance laws to update definitions and procedures under the Unfair Insurance Trade Practices Act and related statutes. It redefines key terms like "insurer" and "customer," changes the Director of Insurance's authority, and updates rules for claims, settlements, and annual reporting. The bill specifically eliminates the Health Insurance Access Act and Health Care Purchasing Pool Act, removing those frameworks from state law. These changes primarily affect insurance companies, consumers purchasing insurance, and the Nebraska Department of Insurance.
Nebraska's LB 168 (signed April 9, 2025) adopts the 340B Contract Pharmacy Protection Act to protect access to federally discounted drugs. It prohibits drug manufacturers from restricting 340B drug deliveries to authorized locations (like contract pharmacies) or demanding extra data (such as patient records) beyond federal requirements. The law directly affects safety-net hospitals, clinics, and other 340B entities that rely on discounted drugs, as well as drug manufacturers and distributors. It ensures these providers can continue using 340B discounts without unnecessary barriers imposed by manufacturers.
